Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)

Size: px
Start display at page:

Download "Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)"

Transcription

1 This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol) vaginal ring Fiasp (insulin aspart) subcutaneous solution Fiasp FlexTouch (insulin aspart) subcutaneous solution pen-injector Kyleena (levonorgestrel) intrauterine device Central Nervous System/ Huntington's Disease Agents Estrogens/ Vaginal Antidiabetics/ Insulins Antidiabetics/ Insulins Contraceptives/ Progestin Intrauterine Devices Austedo is indicated for the treatment of: Chorea associated with Huntington s disease Tardive dyskinesia in adults. Estring is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Fiasp is indicated to improve glycemic control in adults with diabetes mellitus. Fiasp is indicated to improve glycemic control in adults with diabetes mellitus. Kyleena is indicated for prevention of pregnancy for up to 5 years. To provide an additional option for the treatment of chorea associated with Huntington s disease and tardive dyskinesia. To provide an additional option for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. To provide an additional insulin option to improve glycemic control in adults with diabetes mellitus. To provide an additional insulin option to improve glycemic control in adults with diabetes mellitus. To provide an additional option for the prevention of pregnancy C Pg. 1 of 7

2 Odomzo (sonidegib) capsule Omnipod Insulin Infusion Pump insulin infusion disposable pump Skyla (levonorgestrel) intrauterine device Tolak (fluorouracil) cream Trelegy Ellipta (fluticasone furoate/umeclidinium/vil anterol) aerosol powder for inhalation Antineoplastic Agents/ Miscellaneous Antidiabetics/ Supplies Contraceptives/ Progestin Intrauterine Devices Topical/ Dermatology/ Actinic Keratosis Respiratory/ Anticholinergic / Beta Agonist/ Steroid Inhalant Combinations Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Omnipod Insulin Infusion Pump is used to allow continuous subcutaneous insulin infusion in patients with insulin-dependent diabetes. Skyla is indicated to prevent pregnancy for up to 3 years. Tolak is indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Trelegy Ellipta is indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixeddose combination of fluticasone To provide an option for the treatment of advanced basal cell carcinoma. To provide an option for continuous insulin delivery in insulin-dependent diabetes. To provide an additional option for the prevention of pregnancy. To provide an additional option for the treatment of actinic keratosis lesions. To provide an additional option for the maintenance treatment of patients with COPD C Pg. 2 of 7

3 Generic Agents: furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol. lanthanum carbonate chewable tablet Phosphate Binder Agents Lanthanum carbonate is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). To provide an additional generic option to reduce serum phosphate levels. DELETIONS: Brand Agents: Brisdelle (paroxetine mesylate) capsule Central Nervous System/ Psychotherapeutic - Miscellaneous/ Vasomotor Symptom Agents Brisdelle is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Availability of a non-hormonal generic option for the treatment of moderate to severe vasomotor symptoms associated with menopause. The preferred option on the Prescribing Guide - Standard Control is paroxetine mesylate C Pg. 3 of 7

4 Juxtapid (lomitapide mesylate) capsule Renvela (sevelamer carbonate) powder for suspension, tablet Tamiflu (oseltamivir) capsule Cardiovascular/ Antilipemics/ Microsomal Triglyceride Transfer Protein Inhibitors Phosphate Binder Agents Anti-Infectives/ Antivirals/ Influenza Agents Juxtapid is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (HoFH). Renvela is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. Tamiflu is indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours Prophylaxis of influenza A and B in patients 1 year and older. Availability of an additional option for the treatment of homozygous familial hypercholesterolemia. The preferred option on the Prescribing Guide - Standard Control is Repatha (evolocumab). Availability of additional options for control of serum phosphorus in adults with CKD on dialysis. Standard Control include calcium acetate, lanthanum carbonate, sevelamer carbonate, Phoslyra (calcium acetate), and Velphoro (sucroferric oxyhydroxide). Availability of additional options for the treatment and prophylaxis of influenza A and B. Standard Control include oseltamivir and Relenza (zanamivir) C Pg. 4 of 7

5 Tamiflu (oseltamivir) powder for suspension Tegretol XR (carbamazepine phosphate ext-rel) extended-release tablet Anti-Infectives/ Antivirals/ Tamiflu is indicated for: Availability of a generic option for the treatment and Influenza Agents Treatment of acute, uncomplicated prophylaxis of influenza A and B. influenza A and B in patients 2 weeks of age and older who have The preferred option on the Prescribing Guide - been symptomatic for no more than Standard Control is oseltamivir. 48 hours Prophylaxis of influenza A and B in Central Nervous System/ Anticonvulsants patients 1 year and older. Tegretol-XR is indicated for the treatment of epilepsy and the treatment of pain associated with true trigeminal neuralgia. Availability of additional options for the treatment of epilepsy and trigeminal neuralgia. Standard Control include carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam extrel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, tiagabine, topiramate, valproic acid, zonisamide, Fycompa (perampanel), Oxtellar XR (oxcarbazepine ext-rel), Trokendi XR (topiramate ext-rel), and Vimpat (lacosamide) C Pg. 5 of 7

6 REMOVALS: Brand Agents: Alevicyn (emollient) gel Alevicyn (emollient) dermal spray Alevicyn Antipruritic SG (emollient) liquid Topical/ Dermatology/ Wound Care s Topical/ Dermatology/ Wound Care s Topical/ Dermatology/ Wound Care s Alevicyn gel is intended for management of itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Alevicyn dermal spray is intended for the cleansing, irrigation, moistening, debridement and removal of foreign material including microorganisms and debris from exudating wounds, acute and chronic dermal lesions including stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted/donor sites and exit sites. Alevicyn Antipruritic SG is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. Alevicyn Antipruritic SG may also be Availability of generic options for the management of itch and pain associated with dermal irritations and wounds. Standard Control include desonide and hydrocortisone. Availability of generic options for cleansing, irrigation, moistening, debridement and removal of foreign material from wounds. Standard Control include desonide and hydrocortisone. Availability of generic options to manage and relieve the burning, itching and pain experienced with various types of dermatoses C Pg. 6 of 7

7 used to relieve the pain of first and second degree burns. Alevicyn Antipruritic SG helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process. Standard Control include desonide and hydrocortisone C Pg. 7 of 7

Advanced Control Formulary Change Summary Report Effective

Advanced Control Formulary Change Summary Report Effective This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Cystagon (cysteamine bitartrate)

More information

Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society

Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate

More information

Formulary and Program Updates Effective 5/1/18

Formulary and Program Updates Effective 5/1/18 Formulary and Program Updates Effective 5/1/18 Pharmacy & Therapeutics Committee Meeting February 20, 2018 6:30 8:00 PM WELCOME New Committee Members: Peter Robie, MD General Internist practicing in Winston-Salem

More information

ANTICONVULSANT STEP THERAPY

ANTICONVULSANT STEP THERAPY 2019 First Choice VIP Care Plus Formulary Document: 2019 Step Therapy Formulary ID: 19391 Last Updated: 2/2019 Effective Date: 03-01-2019 ANTICONVULSANT STEP THERAPY APTIOM 200 MG APTIOM 400 MG APTIOM

More information

May 2017 P&T Updates

May 2017 P&T Updates May 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives 6 ml per AMPYRA 3 2 2 tablets per day, 30 day BYDUREON 3 2 4 vials per 28 days 5 mcg pen: 1.2 ml per

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019 VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 04/01/2019 Updated 03/2019 AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED

More information

Velphoro (sucroferric oxyhydroxide)

Velphoro (sucroferric oxyhydroxide) STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney

More information

Juxtapid. Juxtapid (lomitapide) Description

Juxtapid. Juxtapid (lomitapide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Juxtapid Page: 1 of 6 Last Review Date: September 20, 2018 Juxtapid Description Juxtapid (lomitapide)

More information

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate

More information

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved. Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.

More information

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 1 ANTICONVULSANTS

More information

ALLERGIC CONJUNCTIVITIS AGENTS

ALLERGIC CONJUNCTIVITIS AGENTS 2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Quarterly pharmacy formulary change notice Provider update Summary: Effective August 1, 2018, the preferred formulary changes detailed in the table below will apply to District of Columbia Healthy Families

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.PMN.04 Effective Date: 11.15.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Kent Kidney Care Centre: Medicines prescribed for people with chronic kidney disease

Kent Kidney Care Centre: Medicines prescribed for people with chronic kidney disease Kent Kidney Care Centre: Medicines prescribed for people with chronic kidney disease Information for patients The following pages offer you information on some of the medicines that you may need. It is

More information

Anticonvulsant Prior Authorization Request

Anticonvulsant Prior Authorization Request Anticonvulsant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth

More information

Step Therapy Requirements. Effective: 03/01/2015

Step Therapy Requirements. Effective: 03/01/2015 Effective: 03/01/2015 Updated 02/2015 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA OXTELLAR XR POTIGA QUDEXY

More information

Kynamro. Kynamro (mipomersen) Description

Kynamro. Kynamro (mipomersen) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION

More information

Summary of Lothian Joint Formulary Amendments

Summary of Lothian Joint Formulary Amendments Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017 VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 01/01/2017 Updated 12/23/2016 ANTICONVULSANTS Aptiom 200 mg tablet Potiga 200 mg tablet Aptiom 400 mg tablet Potiga 300 mg tablet Aptiom

More information

Quarterly pharmacy formulary change

Quarterly pharmacy formulary change Medi-Cal Managed Care L. A. Care Major Risk Medical Insurance Program Provider Bulletin The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018 Pharmacy and

More information

Medications for Epilepsy What I Need to Know

Medications for Epilepsy What I Need to Know Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for

More information

FirstCarolinaCare Insurance Company. Step Therapy Requirements

FirstCarolinaCare Insurance Company. Step Therapy Requirements FirstCarolinaCare Insurance Company Step Therapy Requirements Effective: 12/01/2018 ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION

More information

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E Santa Clara Family Health Plan Cal MediConnect Formulary List of Step Therapy Requirements Effective: 12/01/2018 13027.12E ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET

More information

Step Therapy Requirements

Step Therapy Requirements Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet

More information

2017 Step Therapy Criteria

2017 Step Therapy Criteria FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.

More information

Literature Scan: Phosphate Binders

Literature Scan: Phosphate Binders Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA

More information

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5

More information

ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard)

ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard) ELEVATE Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard) P&T/Formulary Committee Actions 4Q 2017 (Effective January 1, 2018) Marketplace Standard

More information

Report ADDITIONS: Product Brand Agents: Indication. Subcategory. Generic Agents: Gastrointestinal/ Antiemetics

Report ADDITIONS: Product Brand Agents: Indication. Subcategory. Generic Agents: Gastrointestinal/ Antiemetics This report highlights all changes (additions and deletions) to the CVS Caremark Performance Drug List. ADDITIONS: Brand Agents: Diclegis (doxylamine/ pyridoxine delayed release) Gastrointestinal/ Antiemetics

More information

Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers

Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

Anti-Influenza Agents Quantity Limit Program Summary

Anti-Influenza Agents Quantity Limit Program Summary Anti-Influenza Agents Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Agent Indication Dosage & Administration Relenza Treatment of influenza in Treatment of influenza: (zanamivir) patients

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider update Quarterly pharmacy formulary change notice Summary: The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018, Pharmacy and Therapeutics Committee

More information

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee

More information

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol) Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:

More information

Advanced Control Formulary Change Summary Report Effective

Advanced Control Formulary Change Summary Report Effective This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary. ADDITIONS: Brand Agents: Mepron (atovaquone) suspension Mydayis (amphetaminedextroamphetamine)

More information

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $ MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)

More information

Self Report Seizure Survey Summary 2017

Self Report Seizure Survey Summary 2017 Self Report Seizure Survey Summary 2017 Tetrasomy 18p 61 responses 33 had at least one seizure = 54% 8 had a seizure in the last year Valproate (Depakote) 7 Valproate (Depakote, Epilium) 2 Lamotrigene

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Lacosamide (Vimpat) Reference Number: CP.PMN.155 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017 Effective: 01/01/2017 Updated 11/2016 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA GABITRIL OXTELLAR XR POTIGA

More information

HEALTH SHARE/PROVIDENCE (OHP)

HEALTH SHARE/PROVIDENCE (OHP) HEALTH SHARE/PROVIDENCE (OHP) STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered

More information

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Juxtapid (lomitapide)

Juxtapid (lomitapide) Juxtapid (lomitapide) Policy Number: 5.01.599 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Juxtapid

More information

Kynamro. Kynamro (mipomersen) Description

Kynamro. Kynamro (mipomersen) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)

More information

Added, Removed or Changed. Date of Change. No Change

Added, Removed or Changed. Date of Change. No Change One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG

More information

Medicines for anaemia and mineral bone disease

Medicines for anaemia and mineral bone disease Patient Information: Medicines NHS Logo here Medicines for anaemia and mineral bone disease Health & care information you can trust The Information Standard Certified Member Working together for better

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE February 18, 2015 SUBJECT EFFECTIVE DATE January 21, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 21, 2015 Pharmacy Services Vincent D. Gordon, Deputy

More information

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates July 2018 TRADE NAME (generic name) or generic name ADVAIR DISKUS (fluticasone-salmeterol aer powder ba 100-50 mcg/dose) Brand Addition ADVAIR

More information

Non-Opioid Drugs to Treat Neuropathic Pain. March 2018

Non-Opioid Drugs to Treat Neuropathic Pain. March 2018 Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

NMIH 206 NOTES TOPIC. Page 1 of 5

NMIH 206 NOTES TOPIC. Page 1 of 5 NMIH 206 NOTES TOPIC PAGE NUMBER PHARMACOKINETICS 2-15 INFECTIONS & VACCINATIONS 16-18 ANTICOAGULANT & CLOTTING TIMES 19-24 CARDIAC DRUGS: ANGININE & LANOXIN 25-27 ANAESTHETICS 28-31 NUTRITION 36-40 HYPOLIPIDAEMIC

More information

UPDATE Ohana QUEST Integration Medicaid

UPDATE Ohana QUEST Integration Medicaid UPDATE Ohana QUEST Integration Medicaid Preferred Drug List June 29, 2015 Dear Provider: At the June 04, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes

More information

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3001-11 Program Step Therapy - Anticonvulsants Medication/Therapeutic Class Anticonvulsants Depakote, Depakote ER, Felbatol, Keppra,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

PART 12 DRUGS TO BE PRESCRIBED IN CERTAIN CIRCUMSTANCES UNDER THE NHS PHARMACEUTICAL SERVICES SCHEDULE 2

PART 12 DRUGS TO BE PRESCRIBED IN CERTAIN CIRCUMSTANCES UNDER THE NHS PHARMACEUTICAL SERVICES SCHEDULE 2 SCHEDULE 2 DRUGS, MEDICINES AND OTHER SUBSTANCES TO BE ORDERED BY CONTRACTORS IN THE PROVISION OF PRIMARY MEDICAL SERVICES UNDER A GENERAL MEDICAL SERVICES CONTRACT ONLY IN CERTAIN CIRCUMSTANCES 1 Drug,

More information

Opinion 24 July 2013

Opinion 24 July 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4

More information

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist

More information

Prescribing and Monitoring Anti-Epileptic Drugs

Prescribing and Monitoring Anti-Epileptic Drugs Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University

More information

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists

More information

EVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378

EVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior

More information

Seizure medications An overview

Seizure medications An overview Seizure medications An overview Andrew Zillgitt, DO Staff Neurologist Comprehensive Epilepsy Center Department of Neurology Henry Ford Hospital None Disclosures Objectives A lot to review!!!!! Look at

More information

Swine Influenza Update #3. Triage, Assessment, and Care of Patients Presenting with Respiratory Symptoms

Swine Influenza Update #3. Triage, Assessment, and Care of Patients Presenting with Respiratory Symptoms Updated 12:00 p.m. April 30, 2009 Swine Influenza Update #3 Introduction: This document revises our last update which was sent April 28 th, 2009. The most important revisions include the following: 1.

More information

Antiviral Treatment and Prophylaxis for seasonal Influenza QRG 2017/18

Antiviral Treatment and Prophylaxis for seasonal Influenza QRG 2017/18 Antiviral Treatment and Prophylaxis for seasonal Influenza QRG 2017/18 Selection of antiviral therapy for treatment of influenza (definitions + doses on p.2) When indicated, treatment should be started

More information

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR

More information

COMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE

COMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE CHRONIC KIDNEY DISEASE 1 This information is intended to help you understand why you need to take your medicines. There are multiple medicines that are used to control the symptoms related to CKD. You

More information

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018 TEST Network Health Insurance Corporation NetworkCares Step Therapy Last Updated 11/2018 ANTICONVULSANT THERAPY Aptiom Banzel Briviact Celontin Dilantin 30 Mg Capsule Equetro Fycompa 0.5 Mg/ml Oral Susp

More information

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse Management of Epilepsy in Primary Care and the Community Carrie Burke, Epilepsy Specialist Nurse Epilepsy & Seizures Epilepsy is a common neurological disorder characterised by recurring seizures (NICE,

More information

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy

More information

Appendix. TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes. Codes. (1) Fracture locations

Appendix. TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes. Codes. (1) Fracture locations Page 1 Appendix TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes (1) Fracture locations Vertebral fracture Codes ICD-9-CM Diagnosis codes: 733.13, 805.xx, 806.xx ICD-9-CM Procedure

More information

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic

More information

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009 2018 PDP Premier Step Therapy Document September 2018 Aggrenox Y0114_18_33144_I_009 aspirin 25 mg-dipyridamole 200 mg capsule,ext.release 12 hr multiphase drug may be given. Step 1 Drug(s): clopidigrel.

More information

NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT

NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral

More information

STEP THERAPY PROGRAM

STEP THERAPY PROGRAM STEP THERAPY PROGRAM Step Therapy Program Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. For these drugs, Great-West s Special Authorization

More information

The pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.

The pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado. Health Alert Network Tri-County Health Department Serving Adams, Arapahoe and Douglas Counties Phone 303/220-9200 Fax 303/741-4173 www.tchd.org Follow us on Twitter @TCHDHealth and @TCHDEmergency John

More information

Influenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services.

Influenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services. Influenza Therapies Policy Number: 5.01.515 Last Review: 10/2017 Origination: 10/2002 Next Review: 10/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for influenza

More information

Smoking and Nicotine Replacement Therapy (NRT) Lec:5

Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Tobacco use remains the single largest preventable cause of mortality. Cigarette smoke is a complex mixture of an estimated 4800 compounds. Approximately

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription

More information

Epilepsy Medications: The Basics

Epilepsy Medications: The Basics Epilepsy Medications: The Basics B R I A N A P P A V U, M D C L I N I C A L A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F C H I L D H E A L T H A N D N E U R O L O G Y, U N I V E R S I T

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2004-10 Program Prior Authorization/Medical Necessity - Multisource Brand/Modified Release Anticonvulsants Medication/Therapeutic

More information

Calgary Long Term Care Formulary

Calgary Long Term Care Formulary Page 1 of 10 Calgary Long Term Care Formulary Pharmacy & Therapeutics November 2018 Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 10 Contents November 2018... 3 Formulary

More information

Advanced Control Formulary Change Summary Report Effective

Advanced Control Formulary Change Summary Report Effective This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary. ADDITIONS: Brand Agents: Ajovy (fremanezumabvfrm) subcutaneous injection Aristada

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet

More information

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation).

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized

More information

Patient Guide Levonorgestrel and Ethinyl Estradiol Tablets USP (0.1 mg/0.02 mg) and Ethinyl Estradiol Tablets USP (0.

Patient Guide Levonorgestrel and Ethinyl Estradiol Tablets USP (0.1 mg/0.02 mg) and Ethinyl Estradiol Tablets USP (0. Patient Guide Levonorgestrel and Ethinyl Estradiol Tablets USP (0.1 mg/0.02 mg) and Ethinyl Estradiol Tablets USP (0.01 mg) Rx Only This product (like all oral contraceptives) is intended to prevent pregnancy.

More information

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009 2018 2018 Simply Step Therapy Document September 2018 Aptiom APTIOM 200 MG TABLET APTIOM 400 MG TABLET Y0114_18_33074_I_009 APTIOM 600 MG TABLET APTIOM 800 MG TABLET Criteria If the patient has tried a

More information